304 related articles for article (PubMed ID: 28138891)
1. Inflammatory breast cancer in the Netherlands; improved survival over the last decades.
van Uden DJ; Bretveld R; Siesling S; de Wilt JH; Blanken-Peeters CF
Breast Cancer Res Treat; 2017 Apr; 162(2):365-374. PubMed ID: 28138891
[TBL] [Abstract][Full Text] [Related]
2. [Comparative study of inflammatory and non-inflammatory locally advanced breast cancer - the experience of a Moroccan hospital].
Benbrahim Z; Berrada A; Amaadour L; Zahra El M'rabet F; Elfatemi H; Elfakir S; Mellas N; Arifi S
Gynecol Obstet Fertil Senol; 2017 Nov; 45(11):604-608. PubMed ID: 29100820
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory breast cancer: what progress have we made?
Dawood S; Cristofanilli M
Oncology (Williston Park); 2011 Mar; 25(3):264-70, 273. PubMed ID: 21548470
[TBL] [Abstract][Full Text] [Related]
4. Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients.
Chaher N; Arias-Pulido H; Terki N; Qualls C; Bouzid K; Verschraegen C; Wallace AM; Royce M
Breast Cancer Res Treat; 2012 Jan; 131(2):437-44. PubMed ID: 21360074
[TBL] [Abstract][Full Text] [Related]
5. Development of CNS metastases and survival in patients with inflammatory breast cancer.
Uemura MI; French JT; Hess KR; Liu D; Raghav K; Hortobagyi GN; Arun BK; Valero V; Ueno NT; Alvarez RH; Woodward WA; Debeb BG; Moulder SL; Lim B; Tripathy D; Ibrahim NK
Cancer; 2018 Jun; 124(11):2299-2305. PubMed ID: 29579338
[TBL] [Abstract][Full Text] [Related]
6. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study.
Dawood S; Ueno NT; Valero V; Woodward WA; Buchholz TA; Hortobagyi GN; Gonzalez-Angulo AM; Cristofanilli M
Cancer; 2011 May; 117(9):1819-26. PubMed ID: 21509759
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-18 (IL-18) is equally expressed in inflammatory breast cancer and noninflammatory locally advanced breast cancer: A possible association with chemotherapy response.
Aguiar MAN; Wanderley CWS; Nobre LMS; Alencar MRM; Saldanha MDPS; Souza AM; Wong DVT; Barros PG; Almeida PRC; Lima-Júnior RCP; Ribeiro RA
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e138-e144. PubMed ID: 28766916
[TBL] [Abstract][Full Text] [Related]
8. Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory
Monneur A; Goncalves A; Gilabert M; Finetti P; Tarpin C; Zemmour C; Extra JM; Tallet A; Lambaudie E; Jacquemier J; Houvenaeghel G; Boher JM; Viens P; Bertucci F
Oncotarget; 2017 Sep; 8(39):66019-66032. PubMed ID: 29029489
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.
Cristofanilli M; Valero V; Buzdar AU; Kau SW; Broglio KR; Gonzalez-Angulo AM; Sneige N; Islam R; Ueno NT; Buchholz TA; Singletary SE; Hortobagyi GN
Cancer; 2007 Oct; 110(7):1436-44. PubMed ID: 17694554
[TBL] [Abstract][Full Text] [Related]
10. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
Fouad TM; Kogawa T; Liu DD; Shen Y; Masuda H; El-Zein R; Woodward WA; Chavez-MacGregor M; Alvarez RH; Arun B; Lucci A; Krishnamurthy S; Babiera G; Buchholz TA; Valero V; Ueno NT
Breast Cancer Res Treat; 2015 Jul; 152(2):407-16. PubMed ID: 26017070
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy.
Saigal K; Hurley J; Takita C; Reis IM; Zhao W; Rodgers SE; Wright JL
Clin Breast Cancer; 2013 Oct; 13(5):335-43. PubMed ID: 23850216
[TBL] [Abstract][Full Text] [Related]
12. Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.
van Uden DJP; van Maaren MC; Bult P; Strobbe LJA; van der Hoeven JJM; Blanken-Peeters CFJM; Siesling S; de Wilt JHW
Breast Cancer Res Treat; 2019 Jul; 176(1):217-226. PubMed ID: 30972613
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study.
Wu SG; Zhang WW; Wang J; Dong Y; Sun JY; Chen YX; He ZY
Future Oncol; 2019 Feb; 15(5):507-516. PubMed ID: 30378451
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer.
Levine PH; Portera CC; Hoffman HJ; Yang SX; Takikita M; Duong QN; Hewitt SM; Swain SM
Clin Breast Cancer; 2012 Aug; 12(4):232-9. PubMed ID: 22694825
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
Arias-Pulido H; Cimino-Mathews AM; Chaher N; Qualls CR; Joste N; Colpaert C; Marotti JD; Chamberlin MD; Foisey MG; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2021 Dec; 190(3):477-489. PubMed ID: 34542773
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery.
Brzezinska M; Williams LJ; Thomas J; Michael Dixon J
Breast Cancer Res Treat; 2016 Dec; 160(3):387-391. PubMed ID: 27757718
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.
Costa SD; Loibl S; Kaufmann M; Zahm DM; Hilfrich J; Huober J; Eidtmann H; du Bois A; Blohmer JU; Ataseven B; Weiss E; Tesch H; Gerber B; Baumann KH; Thomssen C; Breitbach GP; Ibishi S; Jackisch C; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Jan; 28(1):83-91. PubMed ID: 19901111
[TBL] [Abstract][Full Text] [Related]
20. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
